Tag: corvus pharmaceuticals

July 7, 2019

5 Top Weekly NASDAQ Biotech & Pharma Stocks: Corvus Soars

Which companies were on the rise last week? We take a look at the top five biotech and pharma stocks...
February 6, 2019

Corvus Presents Updated Biomarker and Clinical Results from Lead Pipeline Programs

Corvus Pharmaceuticals (NASDAQ:CRVS) has announced its updated biomarker and clinical results from its two lead programs, CPI-444 and CPI-006. As...
January 11, 2019

Corvus Announces Presentation of Preclinical Data on CPI-818, a First-in-class Covalent Inhibitor of ITK Targeting T-Cell Lymphomas

Corvus Pharmaceuticals (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, announced data...
April 26, 2018

Corvus Pharmaceuticals Announces Initiation of Phase 1/1b Clinical Trial of Investigational Anti-CD73 Antibody, CPI-006

Corvus Pharmaceuticals (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced...
March 2, 2018

Corvus Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results

Corvus Pharmaceuticals (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced...
April 4, 2017

Corvus Presents Provisional Data On CPI-444

Corvus Pharmaceuticals shared interim data from an ongoing clinical study at the American Association for Cancer Research Annual Meeting.
September 29, 2016

Vernalis Announces Results Announcement for the 12 Months Ended 30 June 2016

Vernalis today announces its audited results for the 12 month period ended 30 June 2016.